• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.

作者信息

Al-Naamani Nadine, Thenappan Thenappan

机构信息

Department of Medicine, University of Pennsylvania, Philadelphia, PA.

Department of Medicine, University of Minnesota, Minneapolis, MN.

出版信息

Chest. 2024 Apr;165(4):766-768. doi: 10.1016/j.chest.2023.11.027.

DOI:10.1016/j.chest.2023.11.027
PMID:38599749
Abstract
摘要

相似文献

1
Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.肺动脉高压中的左心疾病表型：治疗考量
Chest. 2024 Apr;165(4):766-768. doi: 10.1016/j.chest.2023.11.027.
2
Results of atrial flow regulator implantation in pulmonary arterial hypertension patients with severe heart failure despite maximal medical therapy.尽管接受了最大程度的药物治疗，但仍患有严重心力衰竭的肺动脉高压患者植入心房血流调节器的结果。
Kardiol Pol. 2024;82(1):75-78. doi: 10.33963/KP.a2023.0167. Epub 2023 Aug 4.
3
Continued Progress in Therapy for Pulmonary Arterial Hypertension.肺动脉高压治疗的持续进展。
N Engl J Med. 2023 Apr 20;388(16):1524-1526. doi: 10.1056/NEJMe2300324. Epub 2023 Mar 6.
4
Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.左心疾病危险因素对肺动脉高压治疗结局的影响。
Chest. 2024 Apr;165(4):967-977. doi: 10.1016/j.chest.2023.10.037. Epub 2023 Nov 10.
5
Managing Pulmonary Arterial Hypertension With Cardiopulmonary Comorbidities.管理伴有心肺合并症的肺动脉高压。
Chest. 2024 Mar;165(3):682-691. doi: 10.1016/j.chest.2023.08.023.
6
Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure.
Eur Respir J. 2021 Sep 23;58(3). doi: 10.1183/13993003.00466-2021. Print 2021 Sep.
7
Raising the bar: triple therapy for pulmonary arterial hypertension associated with congenital heart disease.
Heart. 2024 Feb 12;110(5):309-310. doi: 10.1136/heartjnl-2023-323462.
8
The Pathobiology of Pulmonary Arterial Hypertension.肺动脉高压的病理生理学。
Cardiol Clin. 2022 Feb;40(1):1-12. doi: 10.1016/j.ccl.2021.08.001.
9
StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2.StratosPHere 2：一项针对 BMPR2 基因突变导致的肺动脉高压的羟氯喹和苯丁酸钠的反应适应性随机安慰剂对照 II 期试验的研究方案。
Trials. 2024 Oct 15;25(1):680. doi: 10.1186/s13063-024-08485-z.
10
Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.贝前列素钠联合西地那非治疗左心衰竭合并肺动脉高压患者的疗效及其对血管内皮功能和炎症的影响
Med Sci Monit. 2021 Feb 3;27:e928413. doi: 10.12659/MSM.928413.

引用本文的文献

1
Treatment of pulmonary hypertension after seven world symposia.七次世界研讨会后肺动脉高压的治疗
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342898. doi: 10.1177/17534666251342898. Epub 2025 May 23.
2
The prognostic value of HFA-PEFF score in connective tissue disease-associated PAH: evidence from a cohort study.HFA-PEFF评分在结缔组织病相关肺动脉高压中的预后价值：一项队列研究的证据
BMC Cardiovasc Disord. 2025 Apr 5;25(1):258. doi: 10.1186/s12872-025-04691-y.